The total sample size, n 0 + n 1 is fixed to 100.
The total sample size, n 0 + n 1 is fixed to 100. The sample size for class y = 0 is set to n 0 = 100, and n 1 takes value from 10 to 300.
Real datasets-data preprocessing
A set of real data containing four microarray experiments, with sample size larger than 150, aggregated for this study. We tried to maintain the original labeling and also to follow the data preparing directions used in the papers reporting these data sets, but in several cases we re-labeled samples for reasons which would be given accordingly. The results for the dataset [16] are given in the article. Here we provide a brief description of these data sets [21] :
2.1 Pediatric acute lymphoblastic leukemia [20] , 248 sample points, 5077 features Acute lymphoblastic leukemia (ALL) data set has been obtained from a study on pediatric acute lymphoblastic leukemia [20] . ALL is a complicated disease containing several subtypes. Data points were labeled into six subtypes: T-ALL (43 sample points), E2A-PBX1 (27 sample points), TEL-AML1 (79 sample points), BCR-ABL (15 sample points), MLL (20 sample points), and hyperdiploid with ¿50 chromosomes (64 sample points). The data have been collected using Affymetrixs Human Genome HG U95Av2 array (Santa Clara, CA) and are publicly available at:
<http://www.stjuderesearch.org/data/ALL1>. This microarray chip contains 12,000 probe sets (features) [8, 21] .
We have removed the features in which less than 1 percent of the sample points had a present call or more than 10 percent of the sample points had their values missing. This reduced the total feature size to 5077. The missing values were filled by averaging across all sample points. We labeled the data into two classes: one containing T-ALL, E2A-PBX1 and TEL-AML1 subtypes (149 sample points), the other containing BCR-ABL, MLL and hyperdiploid > 50 subtypes (99 sample points). Hence, the total sample size is 248 [8] .
2.2 Acute myeloid leukemia [16] , 273 sample points, 22,215 features Acute myeloid leukemia (AML) data set has been obtained from a study on the prognostic pro ling of acute myeloid leukemia [16] . The data and the associated clinical information are publicly available at the NIH GEO, under accession number GSE1159. The data have been collected using Affymetrix's Human Genome U133A Array (Santa Clara, CA), which contains 22,215 probe sets (features). The missing values were filled by averaging across all sample points. We labeled the data into two classes according to their karyotypes: one containing 116 normal karyotype samples, the other containing 157 abnormal karyotype samples. Hence, the total sample size is 273 [8, 21] .
Multiple myeloma [24], 234 sample points, 54,613 features
Multiple myeloma (MM) data set has been obtained from a study on MM and monoclonal gammopathy of undetermined significance (MGUS) [24] and [23] . The data were collected using Affymetrixs Human Genome U133 Plus 2.0 Array (Santa Clara, CA) and are publicly available at the NIH Gene Expression Omnibus (GEO), under accession numbers GSE5900 and GSE2658. This microarray chip contains 54,613 probe sets (features) to cover all kinds of gene transcripts and variants.
The original data set is consisted of four subtypes: MM (559 sample points), MGUS (44 sample points), smoldering MM (SMM, 12 sample points), and healthy donors with normal plasma-cell (NPC, 22 sample points). We labeled sample points based on MM sample points vs. the other containing MGUS, SMM, and NPC sample points (78 sample points). Since the number of MM patients is overwhelming and can have significant effects on the efficiency of feature selection and the accuracy of error estimation, we have randomly selected 156 sample points from among the 559 MM sample points and pair them with the 78 sample points of MGUS/SMM/NPC. Hence, the total sample size is 234 [8, 21] .
2.4 Node-negative breast cancer [6] , 175 sample points, 22,215 features
The original study was carried out with frozen tumor samples from breast cancer patients. The authors tried to independently validate the results of a recent study reporting a 76-gene prognostic signature able to predict distant metastases in lymph node-negative breast cancer patients, and to compare the outcome with clinical risk assessment. The study was conducted by TRANSBIG and aimed to identify patients at high risk of early distant metastases [6] . Extracted RNAs from samples went under the microarray analyses using the Affymetrix U133a GeneChip. The quality of the RNA obtained from each tumor sample was assessed via the RNA profile generated by the Agilent bioanalyzer. The gene expression data are publicly available at NIH GEO with accession number GSE7390. As the authors mentioned, the end points considered in this study were time from diagnosis to distant metastases (TDM), which was the end point used to identify the gene signature, and overall survival, defined as time from diagnosis to death from any cause [6] . They used two ways to label the data: 1. Distant metastasis within 5 years vs. distant metastasis free for 5 years; 2. Distant metastasis within 10 years vs. distant metastasis free for 10 years. These labellings would result in a very unbalanced data set.
Therefore, we labeled sample points in the following way: disease-free death < 10 years (77 sample points), disease-free survival > 10 years or disease-free death > 10 years (98 sample points), and 23 censoring sample points (disease-free survival < 10 years) [21] . [20] . The two-sample t-test is implemented and 15 genes are selected. Out of 248 sample points, n 0 = ⌈80r⌉ and n 1 = 80 − n 0 points are randomly selected from class-0 and class-1, respectively, as the training set. The rest of m = 168 points are held out for error estimation computed via equation (16) [24] . The two-sample t-test is implemented and 15 genes are selected. Out of 234 sample points, n 0 = ⌈80r⌉ and n 1 = 80 − n 0 points are randomly selected from class-0 and class-1, respectively, as the training set. The rest of m = 154 points are held out for error estimation computed via equation (16) [6] . The two-sample t-test is implemented and 15 genes are selected. Out of 175 sample points, n 0 = ⌈80r⌉ and n 1 = 80 − n 0 points are randomly selected from class-0 and class-1, respectively, as the training set. The rest of m = 95 points are held out for error estimation computed via equation (16) in the article. The initial ratio of sample sizes is 0.56.
List of Articles
In this section, we list all the papers included in our study. In Table 1 , we show the ordinary article bibliography with the classification problem and source of data (separate sampling vs random sampling). Next, Table 2 Prediction of recurrence and marker discovery of Dukes' B colon cancer 11 [9] Diagnosis of Docetaxel response in human breast cancer 12 [24] Classification of multiple myeloma 13 [12] Biomarker discovery for survival prediction for HCC 14 [11] Squamous vs Nonsquamous NSCLC 15 [5] Subtype of childhood ALL 16 [2] Subtypes of NSCLC 17 [13] Prediction of clinical endpoints of neuroblastoma patients 18 [4] Classification of thyroid nodules 19 [22] Normal vs kidney cancer subtypes by MiRNA 20 [14] Gene expression signature of breast cancer in young women 
